Invalidity dossier
US 10040845
Human cytomegalovirus neutralizing antibodies and use thereof
Current assignee: Institute for Research in Biomedicine
Added 9/21/2026, 10:47:53 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US10040845B2
Title: Human cytomegalovirus neutralizing antibodies and use thereof
Patent number: US10040845B2
Assignee/current assignee: Institute for Research in Biomedicine (IRB); originally assigned to Institute for Research in Biomedicine. Inventors: Antonio Lanzavecchia and Annalisa Macagno.
Application number: US15/716,818
Key dates:
- Prior art date / priority date: 2008-07-16 (noted as an assumption, not a legal conclusion)
- Filing date: 2017-09-27
- Publication date: 2018-08-07
- Anticipated expiration listed: 2029-07-15
- Legal status listed as: Active (with disclaimer that status is an assumption, not a legal conclusion)
Purpose and plain-language scope: The patent relates to human antibodies (and antigen-binding fragments) that bind and neutralize human cytomegalovirus (CMV), and to their use. Based on the classifications and prior-art keywords, the subject matter concerns immunoglobulins against viruses—specifically CMV (an orthoherpesvirus)—including human (primate-origin) antibodies, CDR/variable-region features, antibody fragments such as Fab, Fab′, F(ab′)2, Fv, and single-chain antibodies (scFv). Classifications also indicate possible applications in antiviral and anti-infective preparations, including antibody-containing medicinal preparations and combinations of two or more antibodies. The listed classifications include A61P31/20 (antivirals for DNA viruses) and A61P31/22 (for herpes viruses). Other versions/publications in the family noted in the excerpt include US20180086819A1, US10414817B2, US10889632B2, and US20210087257A1.
Source: https://patents.google.com/patent/[US10040845](/patent/US10040845)/en
What the excerpt does not establish: It does not provide the actual claims, sequence listings, specific CDR or epitope sequences, experimental data, or the precise neutralizing mechanism; it does not confirm title to any particular claim scope, validity, enforceability, or the accuracy of the legal-status and expiration listings (which the source itself labels assumptions). It also does not establish litigation outcomes or prior-art relationships, which are outside the scope of this overview.
Note: This overview relies solely on the supplied excerpt and cites no external sources.
Generated 10/1/2026, 10:01:05 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 10040845. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.